The role of COX-2 in angiogenesis and rheumatoid arthritis

Experimental and Molecular Pathology

Volumn 74, Issue 3, 2003, Pages 282-290

  Woods, James M ^a   Mogollon, Andres ^a   Amin, Mohammad A ^a   Martinez, Rita J ^a   Koch, Alisa E ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Veteran's Administration   (United States)

Author keywords

Angiogenesis; Chemotaxis; COX 2; Endothelial cell; HMVEC; Rheumatoid arthritis; Rofecoxib; Synovial fibroblast; Tube formation

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INTERLEUKIN 1BETA; PROSTAGLANDIN E2; ROFECOXIB;

ANGIOGENESIS; ARTICLE; CELL ACTIVATION; CHEMOTAXIS; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; FIBROBLAST; HUMAN; HUMAN CELL; MICROVASCULATURE; PATHOGENESIS; RHEUMATOID ARTHRITIS; SKIN BLOOD VESSEL; SYNOVIUM; VASCULAR ENDOTHELIUM;

EID: 0038054520     PISSN: 00144800     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4800(03)00019-4     Document Type: Article

References (48)

1. Arnett F.C., Edworthy S.M., Bloch D.A., Mcshane D.J., Fries J.F., Cooper N.S., Healey L.A., Kaplan S.R., Liang M.H., Luthra H.S., Medsger T.A.J., Mitchell D.M., Neustadt D.H., Pinals R.S., Schaller J.G., Sharp J.T., Wilder R.L., Hunder G.G. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:1988;315-324.
2. Berse B., Hunt J.A., Diegel R.J., Morganelli P., Yeo K., Brown F., Fava R.A. Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin. Exp. Immunol. 115:1999;176-182.
3. Blanco A., Habib A., Levy-Toledano S., Maclouf J. Involvement of tyrosine kinases in the induction of cyclo-oxygenase-2 in human endothelial cells. Biochem. J. 312:1995;419-423.
4. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 264:1994;569-571.
5. Bucala R., Ritchlin C., Winchester R., Cerami A. Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. J. Exp. Med. 173:1991;569-574.
6. Chan C.C., Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D., Evans J., Ford-Hutchinson A.W., Forrest M.J., Gauthier J.Y., Gordon R., Gresser M., Guay J., Kargman S., Kennedy B., Leblanc Y., Leger S., Mancini J., O'ncill G.P., Ouellet M., Patrick D., Percival M.D., Perrier H., Prasit P., Rodger I., et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone] a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles . J. Pharmacol. Exp. Ther. 290:1999;551-560.
7. Crofford L.J., Tan B., McCarthy C.J., Hla T. Involvement of nuclear factor kappa B in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes. Arthritis Rheum. 40:1997;226-236.
8. Crofford L.J., Lipsky P.E., Brooks P., Abramson S.B., Simon L.S., Van D.P.L.B. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum. 43:2000;4-13.
9. Crofford L.J., Wilder R.L., Ristimaki A.P., Hajime S., Remmers E.F., Epps H.R., Hla T. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues effects of interleukin-1 beta, phorbol ester, and corticosteroids . J. Clin. Invest. 93:1994;1095-1101.
10. Daniel T.O., Liu H., Morrow J.D., Crews B.C., Marnett L.J. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. 59:1999;4574-4577.
11. Diaz-Flores L., Gutierrez R., Valladares F., Varela H., Perez M. Intense vascular sprouting from rat femoral vein induced by prostaglandins E1 and E2. Anat. Rec. 238:1994;68-76.
12. Dicker A.P., Williams T.L., Grant D.S. Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am. J. Clin. Oncol. 24:2001;438-442.
13. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1:1995;27-31.
14. Form D.M., Auerbach R. PGE2 and angiogenesis. Proc. Soc. Exp. Biol. Med. 172:1983;214-218.
15. Goldstein I.M. Agents that interfere with arachidonic acid metabolism. Gallin J.I., Goldstein I.M., Snyderman R. Inflammation Basic Principles and Clinical Correlates . 1988;935-946 Raven Press Ltd, New York. (eds.).
16. Guo J.S., Cho C.H., Lam Liu E.S., Choy H.T., Wang J.Y., Leung Koo M.W. Antiangiogenic effect of a highly selective cyclooxygenase-2 inhibitor on gastric ulcer healing in rats. Toxicol. Appl. Pharmacol. 183:2002;41-45.
17. Habib A., Creminon C., Frobert Y., Grassi J., Pradelles P., Maclouf J. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2. J. Biol. Chem. 268:1993;23448-23454.
18. Hernandez G.L., Volpert O.V., Iniguez M.A., Lorenzo E., Martinez-Martinez S., Grau R., Fresno M., Redondo J.M. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A roles of the nuclear factor of activated T cells and cyclooxygenase 2 . J. Exp. Med. 193:2001;607-620.
19. Hla T., Neilson K. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA. 89:1992;7384-7388.
20. Hull M.A., Thomson J.L., Hawkey C.J. Expression of cyclooxygenase 1 and 2 by human gastric endothelial cells. Gut. 45:1999;529-536.
21. Jones M.K., Wang H., Peskar B.M., Levin E., Itani R.M., Sarfeh I.J., Tarnawski A.S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs insight into mechanisms and implications for cancer growth and ulcer healing . Nat. Med. 5:1999;1418-1423.
22. Kang R.Y., Freire-Moar J., Sigal E., Chu C.Q. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br. J. Rheumatol. 35:1996;711-718.
23. Kato M., Nishida S., Kitasato H., Sakata N., Kawai S. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs investigation using human peripheral monocytes . J. Pharm. Pharmacol. 53:2001;1679-1685.
24. Katori M., Majima M., Harada Y. Possible background mechanisms of the effectiveness of cyclooxygenase-2 inhibitors in the treatment of rheumatoid arthritis. Inflam. Res. 47 Suppl. 2:1998;S107-S111.
25. Kim J.M., Ho S.H., Park E.J., Hahn W., Cho H., Jeong J.G., Lee Y.W., Kim S. Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis. Arthritis Rheum. 46:2002;793-801.
26. Kimura T., Noda M., Sugihara H., Kashima K., Hattori T. Expression of fibroblast growth factor-2 transcripts in the healing of acetic acid-induced gastric ulcers. Apmis. 107:1999;767-772.
27. Koch A.E. Angiogenesis implications for rheumatoid arthritis . Arthritis Rheum. 41:1998;951-962.
28. Majima M., Isono M., Ikeda Y., Hayashi I., Hatanaka K., Harada Y., Katsumata O., Yamashina S., Katori M., Yamamoto S. Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants. Jpn. J. Pharmacol. 75:1997;105-114.
29. Montesano R., Orci L. Phorbol esters induce angiogenesis in vitro from large-vessel endothelial cells. J. Cell. Physiol. 130:1987;284-291.
30. Myers L.K., Kang A.H., Postlethwaite A.E., Rosloniec E.F., Morham S.G., Shlopov B.V., Goorha S., Ballou L.R. The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum. 43:2000;2687-2693.
31. Nie D., Lamberti M., Zacharek A., Li L., Szekeres K., Tang K., Chen Y., Honn K.V. Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem. Biophys. Res. Commun. 267:2000;245-251.
32. Oliver S.J., Cheng T.P., Banquerigo M.L., Brahn E. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin reduction of vascular endothelial growth factor (VEGF) . Cell. Immunol. 166:1995;196-206.
33. Pietila P., Moilanen E., Seppala E., Nissila M., Lepisto P., Laitinen O., Vapaatalo H. Differences in the production of arachidonic acid metabolites between healthy and rheumatic synovial fibroblasts in vitro. A preliminary study. Scand. J. Rheumatol. 13:1984;243-246.
34. Rooney M., Condell D., Quinlan W., Daly L., Whelan A., Feighery C., Bresnihan B. Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum. 31:1988;956-963.
35. Roshak A.K., Jackson J.R., Mcgough K., Chabot-Fletcher M., Mochan E., Marshall L.A. Manipulation of distinct NFkappaB proteins alters interleukin-1beta-induced human rheumatoid synovial fibroblast prostaglandin E2 formation. J. Biol. Chem. 271:1996;31496-31501.
36. Sakurada S., Kato T., Okamoto T. Induction of cytokines and ICAM-1 by proinflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition by N-acetyl-L-cysteine and aspirin. Int. Immunol. 8:1996;1483-1493.
37. Sano H., Hla T., Maier J.A., Crofford L.J., Case J.P., Maciag T., Wilder R.L. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J. Clin. Invest. 89:1992;97-108.
38. Satoh H., Shino A., Sato F., Asano S., Murakami I., Inatomi N., Nagaya H., Kato K., Szabo S., Folkman J. Role of endogenous basic fibroblast growth factor in the healing of gastric ulcers in rats. Jpn. J. Pharmacol. 73:1997;59-71.
39. Sawaoka H., Tsuji S., Tsujii M., Gunawan E.S., Sasaki Y., Kawano S., Hori M. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab. Invest. 79:1999;1469-1477.
40. Schnitzer T.J., Hochberg M.C. COX-2-selective inhibitors in the treatment of arthritis. Cleve. Clin. J. Med. 69 Suppl. 1:2002;SI20-30.
41. Siegle I., Klein T., Backman J.T., Saal J.G., Nusing R.M., Fritz P. Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue differential elevation of cyclooxygenase 2 in inflammatory joint diseases . Arthritis Rheum. 41:1998;122-129.
42. Stjernschantz J.A.R. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future. 17:1992;691-704.
43. Storgard C.M., Stupack D.G., Jonczyk A., Goodman S.L., Fox R.I., Cheresh D.A. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J. Clin. Invest. 103:1999;47-54.
44. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., Dubois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:1998;705-716.
45. Walsh D.A. Angiogenesis and arthritis. Rheumatology. 38:1999;103-112.
46. Yamada M., Kawai M., Kawai Y., Mashima Y. The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Curr. Eye Res. 19:1999;300-304.
47. Yamada R., Sano H., Hla T., Hashiramoto A., Kawahito Y., Mukai S., Kohno M., Tsubouchi Y., Inoue M., Komatsu A., Inoue K., Kondo M. Selective inhibition of cyclooxygenase-2 with antisense oligodeoxynucleotide restricts induction of rat adjuvant-induced arthritis. Biochem. Biophys. Res. Commun. 269:2000;415-421.
48. Yin G., Liu W., An P., Li P., Ding I., Planelles V., Schwarz E.M., Min W. Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol. Ther. 5:2002;547-554.